Literature DB >> 7800969

Stimulation of immunoprotective mechanisms by OM-85 BV. A review of results from in vivo and in vitro studies.

J Mauël1.   

Abstract

OM-85 BV, an immunomodulating preparation containing extracts from eight commonly pathogenic bacterial species, has been used with success as an oral adjuvant in the prevention of respiratory tract infections. Results from in vitro and in vivo experiments suggest various mechanisms that can underlie this beneficial effect. Thus, exposure of murine macrophages in vitro to OM-85 BV led to stimulation of biochemical and functional parameters associated with the disposal of microorganisms and tumor cells. Similarly, blood-derived human phagocytes were stimulated to express adhesion molecules (LFA-1, MAC-1, p150,95, ICAM-1), to synthesize TNF-alpha and IL-2, and to develop a natural killer activity. These in vitro functions are reflected in the activation of immunological processes in vivo following administration of OM-85 BV per os. Oral treatment of mice and rabbits increased the capacity of the animals to clear bacteria from the blood, an effect that could be ascribed to enhanced functional activity of polymorphonuclear leukocytes. Administration of OM-85 BV per os also led to enhanced salivary IgA levels in man, and in gut and lung secretions in animals. Stimulation of migration and the beneficial effects of OM-85 BV correlated with phagocytosis-induced superoxide production in human bronchoalveolar lavage cells from orally treated individuals. Finally, injection of OM-85 BV was shown to enhance recovery from irradiation in animals, presumably by improving hemopoietic recovery. These findings indicate that OM-85 BV is capable of stimulating both cellular and humoral components of the immune response.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7800969     DOI: 10.1159/000196372

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  12 in total

1.  Efficacy and Safety of OM-85 in Patients with Chronic Bronchitis and/or Chronic Obstructive Pulmonary Disease.

Authors:  Hao Tang; Zheng Fang; Gabriela P Saborío; Qingyu Xiu
Journal:  Lung       Date:  2015-06-05       Impact factor: 2.584

2.  OM85-BV induced the productions of IL-1β, IL-6, and TNF-α via TLR4- and TLR2-mediated ERK1/2/NF-κB pathway in RAW264.7 cells.

Authors:  Hong Luan; Qian Zhang; Le Wang; Chuanxiao Wang; Miao Zhang; Xiaoli Xu; Huan Zhou; Xing'ai Li; Qing Xu; Fan He; Jin Yuan; Yongman Lv
Journal:  J Interferon Cytokine Res       Date:  2014-03-07       Impact factor: 2.607

3.  Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-85 BV) via C-Fos/serum responsive element.

Authors:  R Keul; M Roth; E Papakonstantinou; M Nauck; A P Perruchoud; L H Block
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

4.  Distinct effects of Broncho-Vaxom (OM-85 BV) on gp130 binding cytokines.

Authors:  M Roth; L H Block
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

5.  Changes in cytokine and nitric oxide secretion by rat alveolar macrophages after oral administration of bacterial extracts.

Authors:  E Broug-Holub; J H Persoons; K Schornagel; G Kraal
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

6.  Prevention of recurrent rhinopharyngitis in at-risk children in France: a cost-effectiveness model for a nonspecific immunostimulating bacterial extract (OM-85 BV).

Authors:  Jean-Jacques Pessey; Françoise Mégas; Benoît Arnould; Florence Baron-Papillon
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

7.  Intranasal immunization with a colloid-formulated bacterial extract induces an acute inflammatory response in the lungs and elicits specific immune responses.

Authors:  A Rial; D Lens; L Betancor; H Benkiel; J S Silva; J A Chabalgoity
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

8.  [Not Available].

Authors:  M D Gutiérrez-Tarango; A Berber
Journal:  Clin Drug Investig       Date:  1997       Impact factor: 2.859

9.  Prospective, randomized comparison of OM-85 BV and a prophylactic antibiotic in children with recurrent infections and immunoglobulin A and/or G subclass deficiency.

Authors:  Ferah Genel; Necil Kutukculer
Journal:  Curr Ther Res Clin Exp       Date:  2003-09

10.  Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway.

Authors:  Carmen Parola; Laura Salogni; Xenia Vaira; Sara Scutera; Paolo Somma; Valentina Salvi; Tiziana Musso; Giuseppe Tabbia; Marco Bardessono; Christian Pasquali; Alberto Mantovani; Silvano Sozzani; Daniela Bosisio
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.